WSQMS Homepage

 

Mar 31, 2015

 
Sentiment Analysis: Understand your Healthcare Customers
Beat Widler co-authors article on Applied Clinical Trials

Sentiment analysis is a methodology that is already quite widely used in the consumer goods industry to drive marketing campaigns. The same methodology can give health care organizations a competitive edge in understanding what customers think about their healthcare experience, to help reduce costs and improve care service and to lead to new clinical research and treatments. In addition, it taps into a new channel of pharmacovigilance input information that can enable Marketing Authorization Holders to keep abreast of opinions on the safety of their products in real time.

Read more online



FDA Draft Guidance on the use of electronic Informed Consent
A Q&A guide on the use of electronic Informed Consent in Clinical Investigations

This guidance provides recommendations for clinical investigators, sponsors, and institutional review boards (IRBs) on the use of electronic media and processes to obtain informed consent for FDA-regulated clinical investigations of medical products, including human drug and biological products, medical devices, and combinations thereof.

Read the pdf



Case Study: Using RbM to evaluate and predict site engagement
RbM can do more than just deploy monitors

Understanding study site engagement is very important in clinical trial performance. For example, understanding study site engagement enables study teams to optimize monitoring efforts to improve data cleaning efficiencies and lessen pre-inherited study risks (i.e., country and cultural differences, site technological capabilities, type of monitoring efforts, country CRO performance, etc.), and boost enrollment outcomes.

Read more online



RbM Data reveals: Site screening Due Diligence improves patient dropout and retention
A way to utilize RbM for patient retention

Clinical trial patient retention and dropout continues to be an issue amongst biopharmaceutical sponsors, as patient dropouts minimize the statistical power of clinical trial data, requiring study teams to enroll additional patients. This outcome not only expends project management and patient enrollment resources, but also causes study timeline slippage, and increases the costs associated with developing additional investigational medical product.

Read more online



FDA invites comments on their Guidance for Clinical Trial Sponsors:
Establishment and Operation of Clinical Trial Data Monitoring Committees

The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the collection of information concerning the establishment and operation of clinical trial data monitoring committees.

Read more online

 

You receive this newsletter, because you have subscribed to it.
If you no longer want to receive this newsletter, you can easily leave the list at this Website.You can't view the images in this e-mail? Click here to open it in your browser.

Widler & Schiemann AG - Weinberghöhe 10 B - CH 6300 Zug, Switzerland - VAT number: CHE-472.215.777 MWST - Public Limited Company according to Swiss Common Law - Managing Partner: Dr. Beat Widler, Dr. Peter Schiemann - +41 41 558 9193 - info@wsqms.com - http://www.wsqms.com